S320.2.011 Site # 504 — Natchitoches, Louisiana

S320.2.011 Site # 504 is a clinical research site located in Natchitoches, Louisiana, United States.

Crixeo Clinical Trials Trust Score: 4/100 (FAILING). This profile has not yet been claimed by the site owner.

S320.2.011 Site # 504 has participated in 1 clinical trials.

Therapeutic areas: Acute Decompensated Heart Failure; Renal Dysfunction.

Sponsors: Solvay Pharmaceuticals.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Natchitoches

Browse all research sites in Louisiana · View every site in Natchitoches

• Barnum Medical Research
• Novo Nordisk Investigational Site
• GSK Investigational Site
• KAMP Medical Research
• Research Site
• Natchitoches Internal Medicine
• Otis Barnum D.O.P.C.
• Barnum Internal Medicine /ID# 170343
• Investigational Site Number 840147
• Melinta 306 Study Site
• Synthetic Biologics Investigational SIte
• Pfizer Investigational Site

Sponsor Feasibility Report

Trust Score: 4/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for S320.2.011 Site # 504?

S320.2.011 Site # 504 has a Crixeo Trust Score of 4/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has S320.2.011 Site # 504 conducted?

S320.2.011 Site # 504 has 1 clinical trials on record. Their work covers Acute Decompensated Heart Failure; Renal Dysfunction.

Is S320.2.011 Site # 504 accredited by Crixeo Clinical Trials?

S320.2.011 Site # 504 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about S320.2.011 Site # 504?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.